LANSOPRAZOLE | A200816 | ZYDUS PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al 5 patentsANDA 200816lansoprazole | D.N.J. | 2018-02-12 | Terminated 2021-07-26 | — |
TAKEDA PHARMACEUTICAL COMPANY LIMITED et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al 3 patentsANDA 200816lansoprazole | D.N.J. | 2010-04-05 | Terminated 2014-10-16 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$2.18
per ea
Lowest NADAC/Unit
$1.66
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68382077277LANSOPRAZOLE DR 30 MG ODT | $2.18 | EA | Generic | — | 2026-06-17 |
| 68382077177LANSOPRAZOLE DR 15 MG ODT | $1.66 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.